Progyny (PGNY) Competitors $14.00 +0.02 (+0.14%) (As of 09:25 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PGNY vs. TVTY, ARA, SHC, AGL, VMD, CO, MRAI, BRTX, OTRK, and MGRXShould you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Tivity Health (TVTY), American Renal Associates (ARA), Sotera Health (SHC), agilon health (AGL), Viemed Healthcare (VMD), Global Cord Blood (CO), Marpai (MRAI), BioRestorative Therapies (BRTX), Ontrak (OTRK), and Mangoceuticals (MGRX). Progyny vs. Tivity Health American Renal Associates Sotera Health agilon health Viemed Healthcare Global Cord Blood Marpai BioRestorative Therapies Ontrak Mangoceuticals Progyny (NASDAQ:PGNY) and Tivity Health (NASDAQ:TVTY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking. Which has more risk & volatility, PGNY or TVTY? Progyny has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Tivity Health has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Which has preferable earnings & valuation, PGNY or TVTY? Tivity Health has lower revenue, but higher earnings than Progyny. Tivity Health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProgyny$1.09B1.09$62.04M$0.5824.10Tivity Health$481.25M3.37$104.91M$1.7119.01 Is PGNY or TVTY more profitable? Tivity Health has a net margin of 17.25% compared to Progyny's net margin of 5.03%. Tivity Health's return on equity of 75.94% beat Progyny's return on equity.Company Net Margins Return on Equity Return on Assets Progyny5.03% 11.36% 7.87% Tivity Health 17.25%75.94%13.65% Do insiders and institutionals hold more shares of PGNY or TVTY? 94.9% of Progyny shares are owned by institutional investors. Comparatively, 91.5% of Tivity Health shares are owned by institutional investors. 12.3% of Progyny shares are owned by company insiders. Comparatively, 2.0% of Tivity Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor PGNY or TVTY? Tivity Health received 309 more outperform votes than Progyny when rated by MarketBeat users. However, 71.94% of users gave Progyny an outperform vote while only 52.98% of users gave Tivity Health an outperform vote. CompanyUnderperformOutperformProgynyOutperform Votes10071.94% Underperform Votes3928.06% Tivity HealthOutperform Votes40952.98% Underperform Votes36347.02% Do analysts rate PGNY or TVTY? Progyny currently has a consensus target price of $25.42, suggesting a potential upside of 81.81%. Given Progyny's stronger consensus rating and higher probable upside, analysts clearly believe Progyny is more favorable than Tivity Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Progyny 0 Sell rating(s) 8 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.38Tivity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor PGNY or TVTY? In the previous week, Progyny had 18 more articles in the media than Tivity Health. MarketBeat recorded 18 mentions for Progyny and 0 mentions for Tivity Health. Tivity Health's average media sentiment score of 0.00 beat Progyny's score of -0.05 indicating that Tivity Health is being referred to more favorably in the news media. Company Overall Sentiment Progyny Neutral Tivity Health Neutral SummaryProgyny and Tivity Health tied by winning 9 of the 18 factors compared between the two stocks. Ad Wide Moat ResearchTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. Get Progyny News Delivered to You Automatically Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PGNY vs. The Competition Export to ExcelMetricProgynyhealth & allied services, not elsewhere classified IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$2.02B$5.05B$8.82BDividend YieldN/A6.93%5.17%4.07%P/E Ratio24.1015.62123.8917.66Price / Sales1.095.761,181.4274.22Price / Cash20.5211.3633.6632.53Price / Book2.423.274.684.68Net Income$62.04M$69.56M$119.38M$226.08M7 Day Performance0.58%-0.03%-2.46%-2.03%1 Month Performance-17.03%2.88%-4.07%0.07%1 Year Performance-57.75%-12.30%29.77%24.61% Progyny Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PGNYProgyny3.6189 of 5 stars$14.00+0.1%$25.42+81.5%-57.8%$1.19B$1.09B24.14563TVTYTivity HealthN/A$32.50flatN/A+0.0%$1.62B$481.25M19.01380Analyst ForecastARAAmerican Renal AssociatesN/A$11.52flatN/A+0.0%$397.94M$822.52M44.314,977SHCSotera Health3.6657 of 5 stars$13.21-2.9%$16.50+24.9%-5.2%$3.74B$1.05B52.843,000High Trading VolumeAGLagilon health2.2561 of 5 stars$1.65-1.2%$6.05+266.7%-85.4%$679.83M$4.32B0.001,117Analyst ForecastVMDViemed Healthcare1.8847 of 5 stars$8.80+3.0%N/A+10.9%$342.67M$183.01M31.63630COGlobal Cord BloodN/A$1.25flatN/A+3.3%$151.94M$1.24B1.951,202MRAIMarpai2.0113 of 5 stars$1.64+13.1%$6.00+265.9%+80.2%$19.92M$37.15M-0.62150BRTXBioRestorative Therapies3.7191 of 5 stars$1.49+6.4%$18.00+1,108.1%-22.2%$10.31M$150,000.00-0.927Analyst RevisionNews CoverageGap UpOTRKOntrak2.7304 of 5 stars$1.72-6.0%$45.00+2,516.3%-79.4%$7.26M$12.74M0.00250Gap DownMGRXMangoceuticals0.508 of 5 stars$2.47+6.0%N/A-98.1%$5.80M$730,000.000.003 Related Companies and Tools Related Companies Tivity Health Alternatives American Renal Associates Alternatives Sotera Health Alternatives agilon health Alternatives Viemed Healthcare Alternatives Global Cord Blood Alternatives Marpai Alternatives BioRestorative Therapies Alternatives Ontrak Alternatives Mangoceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PGNY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Progyny, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Progyny With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PGNY Stock Alerts